OncoImmunity
OncoImmunity is a company focused on AI for cancer immunotherapy.
About
NEC Bio B.V. develops groundbreaking therapies for patients globally using advanced AI technologies, focusing on personalized cancer vaccines and next-generation vaccines for infectious diseases. Their core approach involves identifying patient-specific neoantigens for oncology and highly immunogenic antigens for infectious diseases, leveraging proprietary AI/ML technologies like NEC Immune Profiler and NEC B-cell Epitope Predictor. OncoImmunity is tracked on StartupHub with reviews, comparable companies and the facts we hold on the product.
Frequently asked
What does OncoImmunity do?
OncoImmunity is a technology company that offers Software. Its commercial model is B2B. It is based in Oslo, Norway and was founded in 2014. Public records show $5M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has OncoImmunity raised?
OncoImmunity has raised a total of $5M in funding. The most recent round on record is Seed.
Where is OncoImmunity headquartered?
OncoImmunity is headquartered in Oslo, Norway.
When was OncoImmunity founded?
OncoImmunity was founded in 2014.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.